Y-mAbs Therapeutics

Day One Biopharmaceuticals

SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial.

T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges.

Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.

CD8 PET imaging with [(89)Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study.

Domvanalimab combined with zimberelimab as first-line treatment in patients with PD-L1-high, advanced non-small cell lung cancer: Results from the randomized phase 2 ARC-10 study, Part1.

A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950).

SW convergence: 50/100 (Neutral), 0 bullish / 1 bearish signals

A phase Ib/II study of modakafusp alfa alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors.

Botensilimab (Fc-enhanced anti-CTLA-4 antibody) plus balstilimab (anti-PD-1 antibody) in patients with treatment-refractory ovarian cancer.

<article class="bts-verified-summary" data-ticker="YMAB">
<p>Y-mAbs Therapeutics (YMAB) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-3">[3]</a></sup>, including 1 Phase 2<sup><a href="#fn-1">[1]</a></sup>, 1 Phase 1<sup><a href="#fn-2">[2]</a></sup>.</p>
<p>No Form 4 insider filings for YMAB were recorded at the SEC in the past 30 days<sup><a href="#fn-4">[4]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Y-mAbs+Therapeutics%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Y-mAbs+Therapeutics%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-3">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Y-mAbs+Therapeutics%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-4">SEC EDGAR (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22YMAB%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

SEC EDGAR

Y-mAbs Therapeutics (YMAB) — BioTechSigns Verified Summary

Y-mAbs Therapeutics (YMAB) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[3], including 1 Phase 2[1], 1 Phase 1[2].

No Form 4 insider filings for YMAB were recorded at the SEC in the past 30 days[4].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Y-mAbs+Therapeutics%22&aggFilters=status%3Arec%2Cact
[2] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Y-mAbs+Therapeutics%22&aggFilters=status%3Arec%2Cact
[3] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22Y-mAbs+Therapeutics%22&aggFilters=status%3Arec%2Cact
[4] SEC EDGAR. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22YMAB%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11

Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose.

Naxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-DOTA) to assess safety and tolerability